Contact Us

Get 30% Free Customization on This Report

Published Date: May, 2019

Chronic Idiopathic Constipation Therapeutic Market (Drug Class - Emollients, Laxatives, Bulk-forming Agents, Osmotic Agents, and Other Drug Class; Route of Administration - Oral, and Parental; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025


Request Discount Enquire Before Buying

A recent report published by Infinium Global Research on chronic idiopathic constipation therapeutic market provides an in-depth analysis of segments and sub-segments in the global as well as regional chronic idiopathic constipation therapeutic market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional chronic idiopathic constipation therapeutic market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global chronic idiopathic constipation therapeutic market. According to the report, the global chronic idiopathic constipation therapeutic market is projected to grow at a healthy CAGR over the forecast period of 2019-2025.

 

Market Insight

Constipation can be defined as a state of unsatisfactory bowel movement, with characteristics of unusual stools and difficulty in passing stools, or both. Chronic idiopathic constipation (CIC) is an advancing condition without any known cause or identified underlying illness. Chronic idiopathic constipation is one of the most frequent gastrointestinal disorders globally with an evaluation of 35 million population living with chronic idiopathic constipation, affecting approximately 14% of the adults. CIC can be classified into three subtypes: dyssynergic defecation (DD), a problem with rectal evacuation; slow transit constipation; and normal transit constipation, which is the most common subtype. Patients with CIC usually have symptoms such as reduced frequency of defecation, hard or lumpy stools, straining at stool, a sensation of incomplete evacuation or blockage, and some may also complain about abdominal pain and bloating. In general, symptoms are chronic if they have been present for at least 3 months.

 

Changing lifestyle as well as modern food habits causing a decrease in fluid and fiber intake in the diet, changes in water balance and changes in contractility of the colon are the risk factors leading to chronic idiopathic constipation, thereby driving the chronic idiopathic constipation therapeutic market. Additionally, raising awareness about the treatment, increasing geriatric population and easy accessibility of over-the-counter drugs may also fuel the chronic idiopathic constipation therapeutic market. However, less diagnosis due to lack of symptoms for the disease, alternative treatments and insufficient approved treatment for CIC may hinder the growth of the chronic idiopathic constipation therapeutic market. Increase in healthcare expenditure and extensive research in effective drugs manufacturing for treatment will increase the opportunity for chronic idiopathic constipation therapeutic market in the future.

 

Geographically the chronic idiopathic constipation therapeutic market is segmented in regions like North America, Europe, Asia Pacific, Middle East, and Africa. Due to the high prevalence of chronic idiopathic constipation, North-America will dominate the market during the forecast period. The Asia-pacific market is estimated to grow due to the rise in the acceptability of CIC treatments in countries like India and China. Whereas, the Europe market will develop in the future due to key players focus on new treatment and product launch for chronic idiopathic constipation.


Global Chronic Idiopathic Constipation Therapeutic Market

 

Segment Covered

The report on global chronic idiopathic constipation therapeutic market covers segments such as drug class, route of administration, and distribution channel. On the basis of drug class, the sub-markets include emollients, laxatives, bulk-forming agents, osmotic agents, and other drug class. On the basis of route of administration, the sub-markets include oral, and parental. On the basis of distribution channel, the sub-markets include hospital pharmacies, retail pharmacies, and online pharmacies.

 

Companies Profiled:

The report provides profiles of the companies in the market such as GlaxoSmithKline Plc., Bayer AG, Astellas Pharma, Inc., Sanofi S.A., Pfizer, Inc., Ironwood Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, and Other Companies.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of chronic idiopathic constipation therapeutic market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

The Infinium Advantages

Analyst Support

Get free analyst support for the queries before and post purchasing report.

Customer Satisfaction

Be assured of 100% customer satisfaction about the research and get 24X7 customer support.

400% Growth

Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.

Related Reports

sign up for our newsletter